CCO Annual Update
HIV/AIDS Annual Update 2006
Immune Control and Immune Failure in HIV Infection |
Module 1 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Bruce D. Walker, MD, reviews immune correlates of HIV infection and disease progression and describes prospects for the development of immunotherapy for HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the immune correlates of HIV infection and disease progression
- Explain the process of viral adaptation to the host immune response in HIV infection
- Outline prospects for the development of immunotherapy in HIV infection
|
Viral Pathogenesis: HIV Persistence and Resistance in Latent Reservoirs |
Module 2 of 10 |
|
CME Program Director: John P. Phair, MD
- Robert F. Siliciano, MD, PhD
|
|
|
Robert F. Siliciano, MD, PhD, discusses the significance of HIV reservoirs for the persistence of HIV infection and describes the mechanisms underlying viral persistence in the setting of HAART.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the significance of HIV reservoirs for the persistence of HIV infection
- Identify the mechanisms underlying viral persistence in the setting of HAART
- Explain the importance of viral blips in patients receiving suppressive antiretroviral therapy and their association with persistent immune activation
|
Progress of Entry Inhibitors: Where Are We Now and Where Are We Going? |
Module 3 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Daniel R. Kuritzkes, MD, reviews the development of entry inhibitors, a novel of class of antiretroviral therapies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss advantages and disadvantages of entry inhibition as a strategy for control of HIV-1 replication
- Describe CXCR4-CCR5 coreceptor tropism switching and implications for disease progression
- List results of phase II/III trials of CCR5 inhibitors in HIV-infected patients
|
New Drugs for Treatment-Experienced Patients |
Module 4 of 10 |
|
CME Program Director: John P. Phair, MD
- Kimberly Y. Smith, MD, MPH
|
|
|
Kimberly Y. Smith, MD, MPH, describes investigational agents from existing and novel antiretroviral classes in current clinical development for use in treatment-experienced patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify investigational agents from existing and novel antiretroviral classes in current clinical development for use in treatment-experienced patients
- Discuss results from phase II and III studies of new antiretrovirals in treatment-experienced patients
- Describe current clinical strategies for control of HIV disease in treatment-experienced patients
|
Clinical Strategies for Initiation of Antiretroviral Therapy |
Module 5 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Joel E. Gallant, MD, MPH, discusses the rationale for earlier vs later initiation of antiretroviral therapy and describes current treatment options for use in first-line regimens.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the rationale for earlier vs later initiation of antiretroviral therapy
- Review current treatment options for use in first-line antiretroviral regimens
- Describe approaches to managing treatment intolerance and initial failure
|
Management of Pediatric/Adolescent HIV and Transition to Adulthood |
Module 6 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Andrew T. Pavia, MD, discusses issues relating to the treatment and care of HIV-infected children and adolescents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Review risks specific to HIV-infected adolescents
- Discuss strategies for preventing the spread of HIV infection in this population
- Discuss the general approach to treating HIV-infected adolescents, including when to initiate treatment and how to transition young adults from pediatric to adult HIV care
- Describe factors complicating successful treatment of HIV-infected adolescents
|
Management and Emerging Issues in Sexually Transmitted Diseases |
Module 7 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Jeanne Marrazzo, MD, MPH, describes emerging issues in prevention and management of sexually transmitted diseases in HIV-infected patients.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the use of serologic tests to diagnose and manage syphilis, including neurosyphilis, in the HIV-infected patient
- Discuss the current epidemiology of lymphogranuloma venereum in the HIV-infected patient
- Review diagnostic and therapeutic approaches to management of lymphogranuloma venereum in the HIV-infected patient
- List risk factors for infection with quinolone-resistant Neisseria gonorrhoeae including recommendations for treatment
- Explain the role of newly available serologic tests for type-specific antibody to herpes simplex virus and the implications of a positive test in the HIV-infected patient
|
Management Update on Hepatitis/HIV Coinfection |
Module 8 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Mark S. Sulkowski, MD, reviews current and future approaches to treating hepatitis C virus infection and hepatitis B virus infection in patients with HIV.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe current approaches to treating hepatitis C virus (HCV) infection in patients with HIV
- Discuss new therapeutics in development for treatment of HCV
- Describe current approaches to treating hepatitis B virus (HBV) infection in patients with HIV
|
Managing Methamphetamine Abuse in the Setting of HIV Infection |
Module 9 of 10 |
|
CME Program Director: John P. Phair, MD
|
|
Steven Shoptaw, PhD, discusses the converging epidemics of methamphetamine use and HIV infection, and describes interventions that may be effective for treatment of methamphetamine addiction.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the converging epidemics of methamphetamine use and HIV infection and their interrelationship
- Discuss the role of methamphetamine use in transmission of HIV
- Identify interventions that may be effective for treatment of methamphetamine addiction
|
Technological Advances in HIV Prevention |
Module 10 of 10 |
|
CME Program Director: John P. Phair, MD
- Willard Cates, Jr., MD, MPH
|
|
|
Willard Cates, Jr., MD, MPH, describes current and future approaches to the development of HIV prevention technologies.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss practical issues in behavior modification associated with reduced risk of HIV transmission
- Describe current and future approaches to the development of microbicides as HIV prevention tools
- Explain the rationale for the use of antiretroviral therapy within HIV prevention strategies
|
CCO Slidesets
HIV/AIDS Annual Update 2006 Part 1
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 4.00 MB
|
HIV/AIDS Annual Update 2006 Part 2
 |
|
Format: Microsoft PowerPoint (.ppt) |
File size: 723 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|